Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs

Chemical and Pharmaceutical Bulletin

Volumn 57, Issue 9, 2009, Pages 907-913

  Makino, Chisato ^a   Sakai, Hidetoshi ^a   Okano, Akira ^a   Yabuki, Akira ^a  

^a AJINOMOTO CO INC   (Japan)

Author keywords

Dry coated tablet; Erosion matrix tablet; Nateglinide

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL 6000; MAGNESIUM STEARATE; MEGLITINIDE; MICROCRYSTALLINE CELLULOSE; MITIGLINIDE; NATEGLINIDE; REPAGLINIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DESIGN; DRUG SOLUBILITY; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; MATRIX TABLET; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NONHUMAN; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TABLET HARDNESS; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; CYCLOHEXANES; DELAYED-ACTION PREPARATIONS; DOGS; DRUG COMPOUNDING; HYDROGEN-ION CONCENTRATION; HYPOGLYCEMIC AGENTS; PHENYLALANINE; TABLETS; TIME FACTORS;

EID: 70349173273     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.57.907     Document Type: Article

References (8)

1. Kondo N., Japanese Journal of Clinical Medicine, 55 (Suppl.), 159-163 (1997).
2. Ikenoue T., Okazaki K., Fujitani S., Tsuchiya Y., Akiyoshi M., Maki T., Kondo N., Biol. Pharm. Bull., 20, 354-359 (1997).
3. Shinkai H., Nishikawa M., Sato Y., Toi K., Kumashiro I., Seto Y., Fukuma M., Dan K., Toyoshima S., J. Med. Chem., 32, 1436-1441 (1989).
4. Package insert of Fastic® Tablet, Ajinomoto Co., Inc., 2007.
5. Makino C., Ninomiya N., Sakai H., Orita H., Okano A., Yabuki A., Chem. Pharm. Bull., 54, 409-414 (2006).
6. Ono I., Matsuda K., Kanno S., J. Chromatogr. B, 692, 397-404 (1997).
7. Kikuchi M., Diabetes Frontier, 6, 642-651 (1995).
8. Kikuchi M., Nippon Rinsho, 57, 702-708 (1999).